Devgen NV - Product Pipeline Review - Q4 2010

Global Markets Direct, November 2010, Pages: 38

Devgen NV – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Devgen NV - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Devgen NV - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Devgen NV human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Devgen NV with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Devgen NV’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Devgen NV’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Devgen NV in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Devgen NV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Devgen NV.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Devgen NV and identify potential opportunities in those areas.

List of Tables
List of Figures
Devgen NV Snapshot
Devgen NV Overview
Key Information
Key Facts
Devgen NV – Research and Development Overview
Key Therapeutic Areas
Devgen NV – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Devgen NV – Pipeline Products Glance
Devgen NV–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Devgen NV – Drug Profiles
CDE5110
Product Description
Mechanism of Action
R&D Progress
CDE5498
Product Description
Mechanism of Action
R&D Progress
CDE6960
Product Description
Mechanism of Action
R&D Progress
Drug for diabetes
Product Description
Mechanism of Action
R&D Progress
Drug For Obesity
Product Description
Mechanism of Action
R&D Progress
CDE6963
Product Description
Mechanism of Action
R&D Progress
Drug for auto-immune diseases
Product Description
Mechanism of Action
R&D Progress
Inflammation drug
Product Description
Mechanism of Action
R&D Progress
Devgen NV – Pipeline Analysis
Devgen NV – Pipeline Products by Therapeutic Class
Devgen NV Pipeline Products By Target
Devgen NV – Pipeline Products by Molecule Type
Devgen NV - Dormant Projects
Devgen NV – Company Statement
Devgen NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Devgen NV, Deals Volume Summary, 2004 to YTD 2010
Devgen NV, Deals Summary By Region, 2004 to YTD 2010
Devgen NV, Deals Summary, 2004 to YTD 2010
Devgen NV Detailed Deal Summary
Asset Purchase
Devgen Seeds Acquires Assets From Monsanto
Equity Offering
Devgen Completes Private Placement Of $25 Million
Devgen Completes IPO For $43 Million
Monsanto Partners With Devgen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Aerospace and Defense Industry - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Charter Schools - Global Outlook
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Education Services - Global Strategic Business Report
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Aerospace and Defence Industry - Global Strategic Business Report
• International Military and Government Helicopter Survey